News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
348,141 Results
Type
Article (21599)
Company Profile (150)
Press Release (326392)
Section
Business (109564)
Career Advice (888)
Deals (19036)
Drug Delivery (92)
Drug Development (53483)
Employer Resources (84)
FDA (8108)
Job Trends (8185)
News (193682)
Policy (18207)
Tag
Academia (924)
Alliances (29129)
Alzheimer's disease (644)
Approvals (8074)
Artificial intelligence (84)
Bankruptcy (171)
Best Places to Work (5982)
Biosimilars (67)
Biotechnology (71)
Cancer (590)
Cardiovascular disease (63)
Career advice (723)
Cell therapy (103)
Clinical research (43829)
Collaboration (232)
Compensation (73)
COVID-19 (1183)
C-suite (63)
Cystic fibrosis (60)
Data (675)
Diabetes (108)
Diagnostics (1887)
Drug pricing (91)
Earnings (39337)
Employer resources (77)
Events (51118)
Executive appointments (209)
FDA (8391)
Funding (175)
Gene therapy (98)
GLP-1 (493)
Government (1993)
Healthcare (6833)
Infectious disease (1233)
Inflammatory bowel disease (73)
Interviews (119)
IPO (7640)
Job creations (2465)
Job search strategy (661)
Layoffs (257)
Legal (4207)
Lung cancer (102)
Manufacturing (130)
Medical device (2188)
Medtech (2191)
Mergers & acquisitions (11442)
Metabolic disorders (344)
Neuroscience (825)
NextGen Class of 2024 (2722)
Non-profit (2000)
Northern California (737)
Obesity (214)
Opinion (181)
Patents (73)
People (34270)
Pharmaceutical (76)
Phase I (13679)
Phase II (18650)
Phase III (14912)
Pipeline (292)
Policy (70)
Postmarket research (1690)
Preclinical (4930)
Radiopharmaceuticals (156)
Rare diseases (162)
Real estate (3261)
Regulatory (12775)
Research institute (1167)
Resumes & cover letters (141)
Southern California (670)
Startups (2120)
United States (6660)
Vaccines (231)
Weight loss (184)
Date
Today (44)
Last 7 days (363)
Last 30 days (1963)
Last 365 days (19335)
2024 (17689)
2023 (21129)
2022 (27728)
2021 (28769)
2020 (26866)
2019 (22017)
2018 (17052)
2017 (18245)
2016 (17365)
2015 (20052)
2014 (15632)
2013 (13204)
2012 (14020)
2011 (14407)
2010 (13252)
Location
Africa (437)
Asia (25236)
Australia (3345)
California (1641)
Canada (777)
China (154)
Colorado (68)
Connecticut (63)
Europe (52592)
Florida (227)
Illinois (152)
Indiana (115)
Kansas (63)
Maryland (269)
Massachusetts (1373)
Minnesota (97)
New Jersey (607)
New York (481)
North Carolina (413)
Northern California (737)
Ohio (74)
Pennsylvania (395)
South America (626)
Southern California (670)
Texas (218)
Washington State (154)
348,141 Results for "cure pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Code Pharma’s Gammora® Demonstrates Highly Favorable Outcomes Toward a Potential Cure for HIV
November 13, 2024
·
2 min read
Pharm Country
Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA® (edaravone) for People Living with ALS at the European Network to Cure ALS (ENCALS) Meeting 2024
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced results from two studies of RADICAVA® (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting.
June 17, 2024
·
8 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
Business
Cure Rare Disease Expands Leadership Team and Board of Directors to Advance Mission
Cure Rare Disease, a clinical-stage nonprofit biotechnology organization, announces the addition of a Chief Advancement Officer to its leadership team and welcomes three new members to its board of directors.
June 17, 2024
·
3 min read
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Biotech Beach
ACTG Announces Launch of its First HIV Cure Clinical Trial in Africa
ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced the opening of the PAUSE study, the first ACTG HIV cure clinical trial to take place on the African continent.
June 13, 2024
·
5 min read
Press Releases
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
November 18, 2024
·
10 min read
Layoffs
Athira Pharma to Lay Off 70% of Workforce
Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.
September 23, 2024
·
1 min read
·
Angela Gabriel
1 of 34,815
Next
